Monitoring Therapeutic Efficacy by Real-Time Detection of *Mycobacterium tuberculosis* mRNA in Sputum

Nino Mdivani,[1] Haijing Li,[2] Maka Akhalaia,[3] Medea Gegia,[1] Leila Goginashvili,[3] Douglas S. Kernodle,[4] George Khechinashvili,[1] and Yi-Wei Tang[2,4*]

BACKGROUND: Current laboratory methods for monitoring the response to therapy for tuberculosis (TB) rely on mycobacterial culture. Their clinical usefulness is therefore limited by the slow growth rate of *Mycobacterium tuberculosis*. Rapid methods to reliably quantify the response to anti-TB drugs are desirable.

METHODS: We developed 2 real-time PCR assays that use hydrolysis probes to target DNA of the IS6110 insertion element and mRNA for antigen 85B. The nucleic acids are extracted directly from concentrated sputum samples decontaminated with sodium hydroxide and *N*-acetyl-L-cysteine. We prospectively compared these assays with results obtained by sputum mycobacterial culture for patients receiving anti-TB therapy.

RESULTS: Sixty-five patients with newly diagnosed TB and receiving a standardized first-line anti-TB drug regimen were evaluated at week 2 and at months 1, 2, and 4 after therapy initiation. Both the DNA PCR assay (98.5% positive) and the mRNA reverse-transcription PCR (RT-PCR) assay (95.4% positive) were better than standard Ziehl–Neelsen staining techniques (83.1%) for detecting *M. tuberculosis* in culture-positive sputum samples. The overall agreement between culture and mRNA RT-PCR results for all 286 sputum samples was 87.1%, and compared with culture, the mRNA RT-PCR assay's diagnostic sensitivity and specificity were 85.2% and 88.6%, respectively. For monitoring efficacy of therapy, mRNA RT-PCR results paralleled those of culture at the follow-up time points.

CONCLUSIONS: The continued presence of viable *M. tuberculosis* according to culture and results obtained by RT-PCR analysis of antigen 85B mRNA correlated clinically with resistance to anti-TB drugs, whereas the DNA PCR assay showed a high false-positive rate. This mRNA RT-PCR assay may allow rapid monitoring of the response to anti-TB therapy.

© 2009 American Association for Clinical Chemistry

Mycobacterium tuberculosis grows slowly, and its detection in clinical samples requires several weeks with standard culture techniques. This period may delay the microbiologic diagnosis of tuberculosis (TB),[5] compared with the culture times required for most other bacterial infections. The slow growth of *M. tuberculosis* also delays the availability of results for drug-susceptibility assays, which may be necessary to guide therapy. The conversion of sputum culture results from positive to negative within the initial weeks to months of therapy is correlated with the sterilizing activity (i.e., killing of *M. tuberculosis* in tissues) of the anti-TB drug regimen and is considered the best predictor of treatment success (1). Effective treatment regimens rapidly decrease the number of viable *M. tuberculosis* organisms in sputum, with the number of cultivatable bacilli typically reduced by approximately 10-fold within the first 1–2 weeks (2). Because of the slow growth rate of *M. tuberculosis*, however, the results of cultures for samples obtained early in treatment, if such cultures were obtained, would not be available in a timely manner.

The selection of an anti-TB therapy is largely empirical. Patients are generally prescribed a standard first-line anti-TB regimen consisting of 4 antimicrobial agents. Treatment may be modified weeks or months later as the results of tests of antimicrobial-treatment become available. A rapid, reliable method that reflects effective anti-TB drug activity is extremely desirable. In recent years, tests based on nucleic acid amplification techniques have been developed for the direct detection of *M. tuberculosis* in clinical samples (3–9). Mo-

---

lecular techniques have the potential to improve clinical care by dramatically reducing the time required for detection and may provide substantial savings in the overall costs of patient care (4, 10). Because the half-life of bacterial mRNA is extremely short compared with rRNA or genomic DNA, assays that target mycobacterial mRNA better reflect mycobacterial viability (11). The ability of mRNA-based assays to distinguish viable from nonviable organisms suggests that such assays should also be useful in monitoring the efficacy of anti-TB therapy (12), and others have described their use in this context (12–16).

In 2006, a TB rate of 142 cases per 100 000 individuals was reported in the Republic of Georgia, an incidence that is among the highest rates in the WHO European region. Although the case-detection rate for new smear-positive TB cases has increased in recent years, the rate of treatment success remains low: only 73% for new smear-positive cases in the 2005 cohort (17). A major challenge for TB control is the high rate of multidrug-resistant (MDR) TB. In 2006, MDR TB strains caused 6.8% of new cases of active TB, whereas 26.4% of cases in previously treated individuals were caused by MDR strains (18–20). Approximately 25% of all TB cases are managed in Tbilisi, the capital city.

We have developed 2 real-time PCR assays that use hydrolysis probes to detect *M. tuberculosis*–specific DNA and mRNA directly in sputum samples. In a prospective study, we evaluated the performance of the assays for monitoring the response to anti-TB therapy and compared the results with those obtained by mycobacterial culture for patients referred to the National Center of Tuberculosis and Lung Diseases (NCTLD).

Materials and Methods

STUDY COHORT
The study cohort included new cases of pulmonary TB managed at the inpatient and outpatient departments of the NCTLD. Study participants were >15 years of age and resided in Tbilisi. In accordance with the WHO definition, a new case was defined as a patient who had never had treatment for TB or who had taken anti-TB drugs for <1 month (21). All patients in this study were enrolled within the first or second day of treatment initiation. Each new TB case was diagnosed and recruited initially from clinical signs, symptoms, and a chest radiograph; all cases were confirmed by the growth of *M. tuberculosis* in sputum culture. Patients were enrolled in the study from January 2006 through June 2007. The study was approved by the Georgian NCTLD Ethics Committee, and all participants provided written informed consent before study entry. A questionnaire was used in accordance with current standard practices at NCTLD to assess clinical symp-

toms, history of contact with an active TB case, previous diagnosis of TB, and demographic information. Other clinical examinations and procedures, such as radiographic studies, blood hematology tests, smear/stain/culture examinations, and drug-susceptibility testing were conducted according to the National Guidelines. In addition, HIV status was checked for all enrolled patients. Patients were treated with isoniazid, rifampin, ethambutol, and either streptomycin or pyrazinamide and were evaluated every 2 weeks initially and monthly thereafter. Thirteen patients who were enrolled and started on therapy were subsequently found to have negative results in TB cultures and were excluded from the study analysis.

SAMPLE COLLECTION AND PROCESSING
Sputum samples were collected before therapy and at week 2 and months 1, 2, and 4 after initiation of anti-TB therapy. Standard Ziehl–Neelsen techniques with carbol fuschin staining were used to detect acid-fast bacilli (AFB) in sputum smears. For mycobacterial culture, sputum samples were decontaminated with sodium hydroxide and *N*-acetyl-L-cysteine (NaOH-NALC), neutralized with hydrochloric acid, and centrifuged at 3000*g* for 20 min. Treated samples were incubated on Lowenstein–Jensen medium for 8 weeks at 37 °C. Presumptive *M. tuberculosis* isolates were initially identified by the rapidity of growth and the ability to grow on selective media, as has previously been described (20). For each 0.2 mL of a NaOH-NALC–treated sample, 0.9 mL of Lysis Buffer (bioMérieux) was added, and the mixture was stored and shipped at 4 °C to Vanderbilt University Medical Center for nucleic acid extraction and PCR testing (see below). The potential for contamination via amplicon carryover was diminished by chemical modification with uracil *N*-glycosylase (5, 22).

RECOMBINANT PLASMIDS AND CLINICAL ISOLATES
IS6110- and 85B-specific fragments were generated by real-time PCR amplification (see below) and subsequently cloned into the pCR2.1 vector (Invitrogen). The DNA concentration of the recombinant plasmid standards was calibrated by spectrophotometry at 260 nm (22). Each inserted plasmid was adjusted to 10 000 copies/μL and stored at −80 °C. A panel of 12 strains of the *M. tuberculosis* complex, which were either ATCC strains or well-characterized clinical isolates, was included in the study. Strains not members of the *M. tuberculosis* complex, including the *M. avium–intracelluare* complex, *M. kansasii*, *M. scrofulaceum*, *M. paratuberculosis*, and *M. marinum*, were included in the study for evaluating analytical specificity (23).

PHENOTYPIC TESTING FOR ANTIMYCOBACTERIAL SUSCEPTIBILITY

Antimicrobial testing for susceptibility to antimycobacterial drugs was performed with the absolute-concentration method on Lowenstein–Jensen agar slants (24). In brief, a mycobacterial suspension was prepared from the primary culture, and the turbidity was adjusted with sterile saline to 1 McFarland standard. A series of 10-fold dilutions were prepared, and 0.2 mL was inoculated onto media containing the first-line TB drugs streptomycin (4 mg/L), rifampin (40 mg/L), and ethambutol (2 mg/L). Media containing isoniazid (0.2 mg/L) were inoculated with 0.2 mL of a 100-fold dilution of the suspension. All inoculated sets were incubated at 37 °C for 28–42 days. Isolates resistant to both isoniazid and rifampin were defined as MDR TB.

NUCLEIC ACID EXTRACTION

Total nucleic acids were extracted from NaOH-NALC–decontaminated and concentrated sputum samples with the NucliSENS easyMAG system (bioMérieux). In brief, 200 μL of the mixture of NaOH-NALC–treated sputum sample and Lysis Buffer was placed in the instrument according to the default extraction protocol (25). Total nucleic acids were eluted in 55 μL of Elution Buffer (bioMérieux), and 5 μL of each extract was used for nucleic acid amplification. The recombinant plasmids were serially diluted in triplicate with pooled samples of *M. tuberculosis*–negative sputum before nucleic acid extraction. The human β-actin gene (*ACTB*) was amplified as an internal amplification control. The sequences of primers and fluorophore hydrolysis probes for *ACTB* and the real-time PCR protocol have previously been published (22).

REAL-TIME DNA PCR ASSAY

We used a real-time assay that targets the *M. tuberculosis*–specific IS6110 insertion element (26). In brief, 5 μL of extracted nucleic acid was added to 20 μL of a reaction mixture containing 0.8 μmol/L of each primer and 0.4 μmol/L fluorophore hydrolysis probe (final concentrations) and mixed with 25 μL of TaqMan Universal PCR Master Mix (Applied Biosystems). The thermocycling conditions were a 2-min degradation of the preamplified templates at 50 °C and then 40 cycles of denaturation at 95 °C for 15 s and annealing/extension at 58 °C for 60 s (22). Primers (MTB-IS6110-791F, 5′-TAA CCG GCT GTG GGT AGC A-3′; MTB-IS6110-864R, 5′-CGG TGA CAA AGG CCA CGT A-3′) and the fluorophore hydrolysis probe (MTB-IS6110-830MGB, 5′-CTG GGC AGG GTT C-3′) were modified from those previously described (5, 27). Probes were dual-labeled with the reporter dye FAM (6-carboxyfluorescein) at the 5′ end and the quencher MGB (minor-groove binder) at the 3′ end. The assay was performed with an ABI PRISM 7700 Sequence Detection System (Applied Biosystems).

REAL-TIME mRNA REVERSE-TRANSCRIPTION PCR ASSAY

We used a real-time assay that targets the gene for the *M. tuberculosis*–specific antigen 85B (28). In brief, a 25-μL reaction mixture containing 5 μL of extracted total nucleic acids, 0.5 μmol/L each primer, and 0.2 μmol/L hydrolysis probe was mixed with 25 μL TaqMan One-Step RT-PCR 2× Master Mix (Applied Biosystems). Reaction conditions were as follows: reverse transcription at 48 °C for 30 min, initial denaturation at 95 °C for 10 min, and 40 cycles of denaturation (95 °C for 15 s) and annealing/extension (60 °C for 1 min) (29). Primers (MTB-85B-693F, 5′-CGA CCC TAC GCA GCA GAT C-3′; MTB-85B-758R, 5′-TTC CCG CAA TAA ACC CAT AGC-3′) and the fluorophore hydrolysis probe (MTB-85B-719MGB, 5′-TGG TCG CAA ACA ACA C-3′) were modified from those described previously (14). Probes were dual-labeled with the reporter dye FAM at the 5′ end and the quencher MGB at the 3′ end. The assay was performed with an ABI PRISM 7700 Sequence Detection System.

STATISTICAL ANALYSIS

Qualitative results were obtained for each sample tested, and PCR efficiencies were calculated as previously described (23). Assays of samples with quantification cycle values between 38 and 40 were repeated; results were considered positive if the repeat quantification cycle value was ≤38. Groups were compared with the χ^2, Fisher exact, and McNemar tests with the aid of Epi Info™ software (version 3.4; CDC, Atlanta, GA) or SAS (version 9.1; SAS Institute). Odds ratios (ORs), 95% CIs, and *P* values were calculated; *P* values ≤0.05 were considered statistically significant.

Results

Experiments were first performed to determine the assay limit of detection. The recombinant plasmid calibrators were spiked with pooled samples of *M. tuberculosis*–negative sputum. Plasmids covering the range of 0–1024 copies/reaction at 2-fold dilutions were included in the experiment, and assays of each dilution were performed in triplicate. The limits of detection for the 2 PCR assays for the IS6110- and 85B-specific fragments were the same: 4 copies/reaction (1000 copies/mL of sputum). Calibration curves are shown in Figs. 1 and 2 of the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol55/issue9. PCR efficiencies were 1.91 and 1.66 for IS6110-specific and 85B-specific targets, respectively. Both PCR assays were specific for *M. tuberculosis* strains, and samples spiked with mycobacteria

Table 1. Performance of AFB, DNA PCR, and mRNA RT-PCR tests for detecting *Mycobacterium tuberculosis* in culture-positive sputum samples collected at the time of patient recruitment.

Test	Tested, n	Positive, n (%)
AFB (carbol fuschin stain)	65	54 (83.1)
DNA PCR	65	64 (98.5)
mRNA RT-PCR	65	62 (95.4)

other than *M. tuberculosis* (including *M. avium-intracellulare, M. kansasii, M. scrofulaceum, M. paratuberculosis*, and *M. marinum*) were not detected by the PCR.

During the 1.5-year study period, 65 individuals with culture-confirmed TB were enrolled in the study. The study group included 36 males and 29 females, with a mean (SD) age of 36.5 (13.7) years. All enrolled patients tested seronegative for HIV, had newly diagnosed TB, and either had never previously taken TB drugs or had started TB drugs only within 2 days before recruitment into the study. Follow-up sputum samples were available at week 2 and months 1, 2, and 4 of anti-TB therapy for 65, 63, 56, and 37 individuals, respectively.

ACTB was amplified in all nucleic acid extracts prepared from NaOH-NALC–decontaminated and concentrated sputum and spiked plasmid samples, indicating that no complete inhibition had occurred in the nucleic acid amplification reactions. For sputum samples collected before treatment and at each follow-up visit, total nucleic acids were tested by both the DNA PCR and the mRNA reverse-transcription PCR (RT-PCR) assays with hydrolysis probes. Of the 65 sputum samples collected at the recruitment visit, 54 were AFB smear positive, whereas 64 and 62 samples were positive by the DNA PCR assay and the mRNA RT-PCR assay, respectively. The diagnostic sensitivities of the DNA PCR assay (98.5%; OR, 13.04; 95% CI, 1.65–278.71; $P = 0.003$) and the mRNA RT-PCR assay (95.4%; OR, 4.21; 95% CI, 1.01–20.17; $P = 0.024$) were

significantly higher than with the AFB smear (83.1%; Table 1). Results of testing for AFB were significantly different from those for the DNA PCR assay and the mRNA RT-PCR assay ($P = 0.006$, and $P = 0.039$, respectively, McNemar test), and the data for the DNA PCR and mRNA RT-PCR assays were comparable ($P = 0.5$, McNemar test).

When all 286 sputum samples collected at the time of recruitment and during on-treatment follow-up were compared, the DNA PCR assay showed a higher diagnostic sensitivity (93.8% vs 85.2%; OR, 2.61; 95% CI, 1.03–6.81; $P = 0.025$) and a lower diagnostic specificity (51.3% vs 88.6%; OR, 7.39; 95% CI, 3.99–13.82; $P < 0.0001$) than the mRNA RT-PCR assay, when results of mycobacterial culture were used as the standard (Table 2). The overall agreement between the culture and RT-PCR results was 87.1%, which was significantly better than between the culture and DNA PCR results (87.1% vs 70.3%; OR, 2.85; 95% CI, 1.82–4.47; $P < 0.0001$) (Table 2).

Conversion of assay results from positive to negative during therapy was used to indicate effective anti-TB therapy. At 2 weeks of therapy, culture and mRNA RT-PCR results were negative in 21 (32.3%) and 29 (44.6%) of the cases, respectively. After 1, 2, and 4 months of therapy, culture results were negative in 46 (63.0%), 55 (98.2%), and 36 (97.3%) of the cases, respectively. By comparison, the mRNA RT-PCR results were negative at the corresponding therapy times in 45 (72.3%), 48 (86.7%), and 34 (91.9%) of the cases. Results for the mRNA RT-PCR assay agreed with culture results at follow-up time points in 36 (55.4%) of the cases and converted to negative earlier than culture results in 13 cases (20.0%) and later than culture results in 13 cases (20.0%) (Fig. 1). Although these differences from the culture results were not statistically significant ($P > 0.05$), results for the mRNA RT-PCR assay appeared to be more diagnostically sensitive for monitoring treatment response at the 2-week follow-up but to be less sensitive thereafter. A higher false-positive rate was noticed in the late follow-up stage when the DNA PCR assay was used for therapy monitoring (Fig. 1).

Table 2. Performance of DNA and mRNA real-time assays with hydrolysis probes for detecting *Mycobacterium tuberculosis*–specific DNA and mRNA in sputum samples, compared with results for mycobacterial culture.

Real-time assay	C+ P+[a] (true positives), n	C+ P− (false negatives), n	C− P+ (false positives), n	C− P− (true negatives), n	Diagnostic sensitivity, %	Diagnostic specificity, %	Agreement with culture, %
DNA PCR	120	8	77	81	93.8	51.3	70.3
mRNA RT-PCR	109	19	18	140	85.2	88.6	87.1

[a] C, culture; P, DNA or mRNA real-time PCR assay.

Fig. 1. Conversion to negative results for mycobacterial culture, the DNA PCR assay, and the mRNA RT-PCR assay during anti-TB therapy.

Percentage data are presented as proportion and 95% CI.

We then explored the relationships between time to conversion to negative during anti-TB therapy and antimicrobial-susceptibility patterns at treatment initiation. Of 59 non-MDR TB cases, 47 (79.7%) of the cultures turned negative within 1 month of therapy, whereas 5 (83.4%) of 6 MDR TB cases did not turn negative until after at least 2 months of therapy (OR, 19.58; 95% CI, 1.88–488.24; $P = 0.0037$, Fisher exact test) (Table 3). The trend was similar when an RT-PCR assay was used to follow the conversion on anti-TB therapy (OR, 15.00; 95% CI, 1.46–370.50; $P = 0.0086$, Fisher exact test). These results, as determined by both culture and mRNA assays, indicated that patients with non-MDR TB tended to convert to negative more rapidly than those with TB caused by MDR isolates. The

Table 3. Relationship between time to conversion to negative and drug-resistance patterns.

Assay	Drug resistance	Cases, n	Converted to negative, n (%)	
			≤1 Month	≥2 Months
Culture	MDR	6	1 (16.7)	5 (83.4)
	Non-MDR	59	47 (79.7)	12 (20.3)
RT-PCR	MDR	6	1 (16.7)	5 (83.4)
	Non-MDR	56[a]	42 (75.0)	14 (25.0)

[a] Three cases were excluded because they were culture positive but negative in the mRNA RT-PCR assay at the time of patient recruitment.

results of culture and the RT-PCR assay were not significantly different with respect to the time to conversion to negative ($P > 0.5$, Fisher exact test; Table 3).

Discussion

In this prospective study, we used *M. tuberculosis*–specific DNA PCR and mRNA RT-PCR assays to monitor the response to anti-TB therapy. Conversion of assay results from positive to negative during follow-up was considered an indicator of effective therapy. Results with the mRNA RT-PCR assay agreed with culture results at every time point after the initiation of therapy in 55.4% of the cases and predicted conversion earlier in 20.0% of the cases and later in another 20.0% of the cases. Validation of the performance of molecular assays by comparison with the results of a conventional culture may be associated with an artificially decreased diagnostic specificity. Nevertheless, the mRNA RT-PCR assay we have described may provide a rapid real-time tool for monitoring the efficacy of anti-TB therapy.

The emergence and spread of MDR and extensively drug-resistant strains of *M. tuberculosis* pose a serious threat to current anti-TB regimens (*30*). Current therapy involves the initial administration of 4 first-line drugs. The initial regimen is subsequently modified as necessary according to the results of antimicrobial-resistance assays, which may not become available for several months. Current laboratory methods for monitoring the efficacy of TB therapy rely on mycobacterial culture, and the slow growth of *M. tuberculosis* causes delays in obtaining results. Our data obtained with both culture and mRNA assays indicated that patients with resistance to single drugs tended to convert to negative more rapidly than those with TB caused by MDR isolates. This finding makes the mRNA assay attractive, especially in a population with a higher prevalence of MDR disease. DNA target–based molecular methods have not yet met the need for a more rapid test (*10*). Although these assays can shorten the time to verify the presence of *M. tuberculosis* in a clinical sample, they are not specific enough to be used as an index of "test of cure" because bacterial DNA may persist long after the bacteria have been killed (*27*).

Several groups of investigators have described efforts to use mRNA target–based assays to rapidly monitor treatment efficacy (*12–16*). The concentrations of *M. tuberculosis* mRNA decline after the initiation of therapy, as do counts of viable *M. tuberculosis* colonies, with 90% of patients becoming negative for both markers within 2 months of treatment (*13, 14*). The rapid disappearance of *M. tuberculosis* mRNA from sputum suggests that it is a good index of microbial viability and a useful marker for assessing the response to ther-

apy. In our study, we used a high concentration of guanidine isothiocyanate in Lysis Buffer to stabilize *M. tuberculosis* mRNA in sputum samples immediately after they had been decontaminated and concentrated with NaOH-NALC. Our evaluation of 65 new TB cases showed that the results for the mRNA RT-PCR assay agreed well with culture results at most follow-up time points. Furthermore, the mRNA result turned negative in 13 cases (20.0%) at the first follow-up time point at week 2, while the culture result remained positive. Similar to the culture results, the time to the conversion of the mRNA result to negative correlated with susceptibilities to anti-TB drugs. Cases involving strains with only isoniazid resistance responded more quickly to anti-TB therapy than cases of MDR TB. The mRNA RT-PCR assay can be used as a rapid and real-time tool for assessing the clinical response to anti-TB therapy, replacing more time-consuming phenotypic assays of antimicrobial susceptibility.

Our RT-PCR protocol was designed to amplify and detect mRNA only from concentrated and decontaminated sputum samples. Because the NucliSENS easyMAG extraction system recovers total nucleic acids, we could not avoid residual background amplification of DNA encoding the gene for the 85B antigen. This result may explain a slightly delayed TB conversion at later follow-up time points, compared with the culture results. Techniques that can either specifically recover mRNA or destroy residual DNA during extraction may enhance the performance of the mRNA RT-PCR assay (31, 32). Another potential way to enhance performance is based on emerging evidence that certain host cytokine responses are associated with effec-

tive therapy (33–35). Combining assays to measure both *M. tuberculosis* transcripts and changes in the host response may ultimately prove even better for monitoring the response to anti-TB therapy (36–38).

References

1. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Resp Dis 1993;147: 1062–3.

2. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Resp Dis 1980;121:939–49.

3. Brisson-Noel A, Gicquel B, Lecossier D, Levy-Frebault V, Nassif X, Hance AJ. Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. Lancet 1989;2:1069–71.

4. Kaul KL. Molecular detection of *Mycobacterium tuberculosis*: impact on patient care. Clin Chem 2001;47:1553–8.

5. Tang YW, Meng S, Li H, Stratton CW, Koyamatsu T, Zheng X. PCR enhances acid-fast bacillus stain-based rapid detection of *Mycobacterium tuberculosis.* J Clin Microbiol 2004;42:1849–50.

6. Thwaites GE, Caws M, Chau TT, Dung NT, Campbell JI, Phu NH, et al. Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception

of antituberculosis chemotherapy. J Clin Microbiol 2004;42:996–1002.

7. Shankar P, Manjunath N, Mohan KK, Prasad K, Behari M, Shriniwas, Ahuja GK. Rapid diagnosis of tuberculous meningitis by polymerase chain reaction. Lancet 1991;337:5–7.

8. Drosten C, Panning M, Kramme S. Detection of *Mycobacterium tuberculosis* by real-time PCR using pan-mycobacterial primers and a pair of fluorescence resonance energy transfer probes specific for the *M. tuberculosis* complex. Clin Chem 2003;49:1659–61.

9. Walker GT, Nadeau JG, Linn CP, Devlin RF, Dandliker WB. Strand displacement amplification (SDA) and transient-state fluorescence polarization detection of *Mycobacterium tuberculosis* DNA. Clin Chem 1996;42:9–13.

10. Tang YW, Procop GW, Persing DH. Molecular diagnostics of infectious diseases. Clin Chem 1997;43:2021–38.

11. Fenhalls G, Stevens L, Moses L, Bezuidenhout J, Betts JC, van Helden P, et al. In situ detection of *Mycobacterium tuberculosis* transcripts in human lung granulomas reveals differential gene expres-

sion in necrotic lesions. Infect Immun 2002;70: 6330–8.

12. Aellen S, Que YA, Guignard B, Haenni M, Moreillon P. Detection of live and antibiotic-killed bacteria by quantitative real-time PCR of specific fragments of rRNA. Antimicrob Agents Chemother 2006;50:1913–20.

13. Desjardin LE, Perkins MD, Wolski K, Haun S, Teixeira L, Chen Y, et al. Measurement of sputum *Mycobacterium tuberculosis* messenger RNA as a surrogate for response to chemotherapy. Am J Resp Crit Care Med 1999;160:203–10.

14. Jou NT, Yoshimori RB, Mason GR, Louie JS, Liebling MR. Single-tube, nested, reverse transcriptase PCR for detection of viable *Mycobacterium tuberculosis.* J Clin Microbiol 1997;35:1161–5.

15. Eltringham IJ, Drobniewski FA, Mangan JA, Butcher PD, Wilson SM. Evaluation of reverse transcription-PCR and a bacteriophage-based assay for rapid phenotypic detection of rifampin resistance in clinical isolates of *Mycobacterium tuberculosis.* J Clin Microbiol 1999;37:3524–7.

16. Hu Y, Mangan JA, Dhillon J, Sole KM, Mitchison DA, Butcher PD, Coates AR. Detection of mRNA

transcripts and active transcription in persistent *Mycobacterium tuberculosis* induced by exposure to rifampin or pyrazinamide. J Bacteriol 2000; 182:6358–65.

17. World Health Organization (WHO). Global tuberculosis control: surveillance, planning, financing: WHO report 2008. Geneva: WHO; 2008. Publication WHO/HTM/TB/2008.393.

18. Mdivani N, Zangaladze E, Volkova N, Kourbatova E, Jibuti T, Shubladze N, et al. High prevalence of multidrug-resistant tuberculosis in Georgia. Int J Infect Dis 2008;12:635–44.

19. Weinstock DM, Hahn O, Wittkamp M, Sepkowitz KA, Khechinashvili G, Blumberg HM. Risk for tuberculosis infection among internally displaced persons in the Republic of Georgia. Int J Tuberc Lung Dis 2001;5:164–9.

20. Gegia M, Mdivani N, Mendes RE, Li H, Akhalaia M, Han J, et al. Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations. Antimicrob Agents Chemother 2008;52:725–9.

21. World Health Organization (WHO). Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Geneva: WHO; 2003. Publication WHO/CDS/TB/2003.313.

22. Li H, Dummer JS, Estes WR, Meng S, Wright PF, Tang YW. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol 2003;41:187–91.

23. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611–22.

24. Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of *Mycobacterium tuberculosis* from northwestern Russia: implications for genotypic resistance testing. J Clin Microbiol 2002; 40:3810–3.

25. Tang YW, Sefers SE, Li H, Kohn DJ, Procop GW. Comparative evaluation of three commercial systems for nucleic acid extraction from urine specimens. J Clin Microbiol 2005;43:4830–3.

26. Cave MD, Eisenach KD, McDermott PF, Bates JH, Crawford JT. IS6110: conservation of sequence in the *Mycobacterium tuberculosis* complex and its utilization in DNA fingerprinting. Mol Cell Probes 1991;5:73–80.

27. Desjardin LE, Chen Y, Perkins MD, Teixeira L, Cave MD, Eisenach KD. Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis. J Clin Microbiol 1998; 36:1964–8.

28. De Wit L, de la Cuvellerie A, Ooms J, Content J. Nucleotide sequence of the 32 kDa-protein gene (antigen 85 A) of *Mycobacterium bovis* BCG. Nucleic Acids Res 1990;18:3995.

29. Li H, McCormac MA, Estes RW, Sefers SE, Dare RK, Chappell JD, et al. Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections. J Clin Microbiol 2007;45:2105–9.

30. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009;7:81–7.

31. Desjardin LE, Perkins MD, Teixeira L, Cave MD, Eisenach KD. Alkaline decontamination of sputum specimens adversely affects stability of mycobacterial mRNA. J Clin Microbiol 1996;34: 2435–9.

32. Honore-Bouakline S, Vincensini JP, Giacuzzo V, Lagrange PH, Herrmann JL. Rapid diagnosis of extrapulmonary tuberculosis by PCR: impact of sample preparation and DNA extraction. J Clin Microbiol 2003;41:2323–9.

33. Mistry R, Cliff JM, Clayton CL, Beyers N, Mohamed YS, Wilson PA, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 2007;195: 357–65.

34. Siawaya JF, Bapela NB, Ronacher K, Beyers N, van Helden P, Walzl G. Differential expression of interleukin-4 (IL-4) and IL-4δ2 mRNA, but not transforming growth factor beta (TGF-β), TGF-βRII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. Clin Vaccine Immunol 2008;15:1165–70.

35. Ribeiro-Rodrigues R, Resende Co T, Johnson JL, Ribeiro F, Palaci M, Sá RT, et al. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol 2002;9:818–23.

36. Dietze R, Teixeira L, Rocha LM, Palaci M, Johnson JL, Wells C, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001;45: 1972–6.

37. O'Brien RJ. Studies of the early bactericidal activity of new drugs for tuberculosis: a help or a hindrance to antituberculosis drug development? Am J Respir Crit Care Med 2002;166:3–4.

38. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000;45:859–70.